Cat. No.: HY-N0753

Eupalinolide B

Avis client

Based on 1 Customer Validation

Eupalinolide B is a germ sesquiterpene. Eupalinolide B can be isolated from Eupatorium lindleyanum. Eupalinolide B induces Apoptosis, elevates ROS, promotes Autophagy. regulates GSK-3β/β-catenin, targets UBE2D3 and TAK1, activates ROS-ER-JNK, inhibits NF-κB and MAPKs. Eupalinolide B has anticancer activity against pancreatic cancer and liver cancer. Eupalinolide B relieves rheumatoid arthritis, acute lung injury, periodontitis, depression.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.27%
CAS No.: 877822-41-8
Formule: C₂₄H₃₀O₉
Masse moléculaire:462.49

Stockage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Eupalinolide B Chemical Structure

CAS No.: 877822-41-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform GSK-3 :

Voir tous les produits spécifiques à Isoform MAP3K :

Voir tous les produits spécifiques à Isoform JNK :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform p38 MAPK :

In Vitro

Eupalinolide B (0-10 μM; 24 h) inhibits the viability of pancreatic cancer cell lines MiaPaCa-2, PANC-1, and PL-45 more significantly than normal pancreatic cells HPNE^[1].
Eupalinolide B (0-32 μM; 48 h) reduces the viability of RA-FLS in a concentration-dependent manner^[2].
Eupalinolide B (0-10 μM; 1 h) inhibits the production of NO in LPS-stimulated RAW264.7 cells in a dose-dependent manner, with an IC₅₀ value of 2.24 μM^[3].
Eupalinolide B (6-24 μM; 24-72 h) significantly inhibits the growth of human hepatocarcinoma cell lines SMMC-7721 and HCCLM3^[4].
EB (6-24 μM; 24 h) inhibits the migration of human hepatic carcinoma cells (SMMC-7721 and HCCLM3) via activating ROS-ER-JNK signaling pathway^[4].
Eupalinolide B (0.125-1 μM; 48 h) promotes Corticosterone (HY-B1618)-induced PC12 cell proliferation and improve cell viability^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

RA-FLS
Concentration:

4, 8, 16 μM
Incubation Time:
Result:

Increased the ratios of p-AMPK/t-AMPK and p-ULK-1/t-ULK-1 and decreased the p-mTOR/t-mTOR ratio.

Immunofluorescence^[2]

Cell Line:

RA-FLS
Concentration:

4, 8, 16 μM
Incubation Time:

48 h
Result:

Elevated LC3B levels and decreased P62 expression.

In Vivo

Eupalinolide B (20-40 mg/kg; i.p.; daily; 4 weeks) shows antitumor effects in a xenograft mouse model of pancreatic cancer^[1].
Eupalinolide B (8-16 mg/kg; i.p.; daily; 2 weeks) alleviates rheumatoid arthritis in adjuvant-induced arthritis (AIA) rats^[2].
Eupalinolide B (5-20 mg/kg; i.p.; administered 2 h before and 6 h, 18 h after LPS treatment) significantly alleviates LPS-induced acute lung injury in mice, manifested as a reduction in lung injury score, myeloperoxidase activity^[3].
Eupalinolide B (25-50 mg/kg; i.p.; every 2 days; 3 weeks) significantly inhibits the growth of tumors formed by human hepatocarcinoma cell lines SMMC-7721 or HCCLM3 in nude mice, reducing tumor volume and weight^[4].
Eupalinolide B (30 mg/kg; i.p.; daily; 14 days) can effectively improve periodontal inflammatory damage in a mouse periodontitis model and inhibit alveolar bone resorption^[5].
Eupalinolide B (5-20 mg/kg; i.p.; once a day; 22 to 35 days after CUMS exposure) can improve the depressive-like behavior of CUMS rats, reduce hippocampal tissue pathological damage, and promote hippocampal neurogenesis^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude mice (male, 5-week-old); xenograft tumor model of pancreatic cancer^[1]
Dosage:

20 mg/kg or 40 mg/kg (dissolved in saline)
Administration:

Intraperitoneal injection, daily for 4 weeks
Result:

Significantly slowed tumor growth in the nude mice.
Reduced tumor volume and weigh.
Revealed a decrease in Ki-67 expression.
Inhibited cell proliferation.

Animal Model:

Sprague-Dawley rats (male, 4-week-old); adjuvant-induced arthritis (AIA) model^[2]
Dosage:

8 mg/kg or 16 mg/kg
Administration:

Intraperitoneal injection, daily for 2 weeks
Result:

Reduced hind paw swelling and the arthritis index.
Down-regulated the serum levels of inflammatory cytokines TNF-α, IL-1β, and MCP-1.
Attenuated inflammatory cell infiltration, pannus formation, and synovial hyperplasia.
Reduced Ki67 expression, increased the number of apoptotic cells, and enhanced autophagy in the synovial tissues.

Chemical Information

CAS No. 877822-41-8
Appearance Solid
Masse moléculaire 462.49
Formule C₂₄H₃₀O₉
Color White to off-white
SMILES

O=C(O[C@@H]1C/C(COC(C)=O)=C/C[C@H](OC(C)=O)/C(C)=C/[C@@]([C@]1([H])C2=C)([H])OC2=O)/C(C)=C/CO
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Plants
- Compositae
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (216.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1622 mL

10.8110 mL

21.6221 mL

5 mM

0.4324 mL

2.1622 mL

4.3244 mL

10 mM

0.2162 mL

1.0811 mL

2.1622 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Huang Q, et al. Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. iScience. 2024 Jul 14;27(8):110496. [Content Brief]

[2]. Gu SL, et al. Eupalinolide B alleviates rheumatoid arthritis through the promotion of apoptosis and autophagy via regulating the AMPK/mTOR/ULK-1 signaling axis. Int Immunopharmacol. 2025 Feb 20;148:114179. [Content Brief]

[3]. Yang L, et al. Eupalinolide B attenuates lipopolysaccharide-induced acute lung injury through inhibition of NF-κB and MAPKs signaling by targeting TAK1 protein. Int Immunopharmacol. 2022 Oct;111:109148. [Content Brief]

[4]. Zhang Y, et al. Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway. Acta Biochim Biophys Sin (Shanghai). 2022 Jul 25;54(7):974-986. [Content Brief]

[5]. Kuang W, et al. Eupalinolide B inhibits periodontitis development by targeting ubiquitin conjugating enzyme UBE2D3. MedComm (2020). 2025 Jan 14;6(1):e70034. [Content Brief]

[6]. Wang TT, et al. Eupalinolide B alleviates corticosterone-induced PC12 cell injury and improves depression-like behaviors in CUMS rats by regulating the GSK-3β/β-catenin pathway. Biochem Pharmacol. 2025 May;235:116831. [Content Brief]

[7]. Yang NY, et al. Cytotoxic sesquiterpene lactones from Eupatorium lindleyanum. J Asian Nat Prod Res. 2007 Apr-Aug;9(3-5):339-45. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1622 mL	10.8110 mL	21.6221 mL	54.0552 mL
	5 mM	0.4324 mL	2.1622 mL	4.3244 mL	10.8110 mL
	10 mM	0.2162 mL	1.0811 mL	2.1622 mL	5.4055 mL
	15 mM	0.1441 mL	0.7207 mL	1.4415 mL	3.6037 mL
	20 mM	0.1081 mL	0.5406 mL	1.0811 mL	2.7028 mL
	25 mM	0.0865 mL	0.4324 mL	0.8649 mL	2.1622 mL
	30 mM	0.0721 mL	0.3604 mL	0.7207 mL	1.8018 mL
	40 mM	0.0541 mL	0.2703 mL	0.5406 mL	1.3514 mL
	50 mM	0.0432 mL	0.2162 mL	0.4324 mL	1.0811 mL
	60 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9009 mL
	80 mM	0.0270 mL	0.1351 mL	0.2703 mL	0.6757 mL
	100 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5406 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Eupalinolide B

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Voir tous les produits spécifiques à Isoform GSK-3

Voir tous les produits spécifiques à Isoform MAP3K

Voir tous les produits spécifiques à Isoform JNK

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform p38 MAPK

Activité biologique

Chemical Information